Bli medlem
Bli medlem

Du är här

2021-04-12

EQL Pharma's CFO has chosen to leave her position

EQL Pharma AB's (publ) Chief Financial Officer (CFO) Jennie Sterning has chosen to leave her position. Jennie has been active in EQL Pharma since 2007 and CFO since 2016. Jennie will remain as CFO until mid-July.

- During her time at EQL Pharma, Jennie has built and developed EQL's finance function. She has also implemented financial management and the GDPR regulations within EQL. Recently, she has focused on the conversion to IFRS and the preparations for EQLs move to Nasdaq Stockholm's main exchange. I want to thank her for an invaluable effort for many years with us. We wish her best of luck with her new challenges, says Christer Fåhraeus, CEO of EQL Pharma.

A process to recruit a new CFO will begin soon. Emanuel Eriksson will take over as acting CFO during the period from Jennie Sterning's last day until a new long-term CFO is in place. Emanuel has a degree in business administration from Lund University with a focus on Technology Management. He has held senior positions in banking as a company manager and in acquisition financing (M&A). Emanuel is currently investment manager for Fårö Capital, where he has coordinated several IPOs in the past year. He has solid experience of the stock market and investor relations.

For further information, please contact:

Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.